Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats

Afatinib, as the first-line treatment for non-small cell lung cancer (NSCLC), causes severe gastrointestinal adverse reactions that greatly affect patients' quality of life and even potentially result in treatment discontinuation. Multiple dose adjustments and concomitant use of anti-diarrheal...

Full description

Bibliographic Details

Published in:	Neoplasia: An International Journal for Oncology Research
Main Authors:	Li Zhang, Anna Hu, Yan Wang, Yuxin Yang, Yalan Liu, Lian Xu, Lei Wang, Zeneng Cheng
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Subjects:	Afatinib Diarrhea management DPP4 Sitagliptin GLP-23-33 Gut microbiota
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558623000477